Skip to main content

Table 5 Treatments and clinical outcomes

From: Comparison of the clinical characteristics in parents and their children in a series of family clustered Mycoplasma pneumoniae infections

Variables

Parents b ( n  = 57)

Children b ( n  = 55)

χ 2 /t value

p value

Macrolides, n (%)

8 (14.0)

53 (96.4)

76.499

 < .001

Tetracyclines, n (%)

1 (1.8)

14 (25.5)

13.555

 < .001

Quinolones, n (%)

55 (96.5)

2 (3.6)

96.567

 < .001

Other antibioticsa, n (%)

2 (3.5)

8 (14.5)

2.946

0.086

Methylprednisolone, n (%)

5 (8.8)

36 (65.5)

38.754

 < .001

Intravenous immunogloblin, n (%)

0 (0)

2 (3.6)

0.546

0.460

Required oxygen, n (%)

13 (22.8)

15 (27.3)

0.298

0.585

ICU admission, n (%)

0 (0)

1 (1.8)

NA

0.491

Total duration of fever (d)

4.1 ± 2.2

5.6 ± 2.2

3.270

0.002

Length of stay in hospital (d)

8.0 ± 2.5

7.1 ± 2.4

-1.766

0.080

Change of macrolides to alternative therapy, n (%)

4 (7.0)

19 (34.5)

12.998

 < .001

MPP, n (%)

51 (89.5)

46/52 (88.5)

0.028

0.866

SMPP, n (%)

0 (0)

10 (18.2)

9.254

0.002

Mechanical ventilation, n (%)

0 (0)

0 (0)

NA

NA

Death, n (%)

0 (0)

0 (0)

NA

NA

  1. Data are presented as means ± SD or number (%)
  2. aOther types of antibiotics are carbapenems (such as meropenem and imipenem) and aminoglycosides (such as etimicin)
  3. bAll % calculated for 57 or 55 patients, respectively, unless stated otherwise. In case % were calculated for less than the maximal number of patients, data for some patients were missing and the actual denominator is displayed
  4. Abbreviations NA Not available, ICU Intensive care unit, MPP Mycoplasma pneumoniae pneumonia, SMPP Severe Mycoplasma pneumoniae pneumonia